Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Neoplasms
Conditions
Keywords
Epithelial Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer, Epidermal Growth Factor, Platinum Hypersensitivity, Hycamtin, Gefitinib, Iressa, Topotecan, EGFR
Brief summary
The purposes of this study are: 1. To determine the dose limiting toxicity (DLT) and the maximum tolerated dose (MTD) weekly of topotecan in combination with standard dose gefitinib in patients with relapsed, platinum-resistant, ovarian, peritoneal or fallopian tube cancers that are epidermal growth factor receptor (EGF-R) positive (\>/= 1+). 2. To determine the response rate and response duration in this patient population treated with the maximum tolerated dose (MTD) of topotecan administered on a weekly schedule in combination with standard dose gefitinib, given by way of the mouth (PO) daily.
Detailed description
Gefitinib inhibits the activity of a molecule present on the cancer cell that plays a role in cancer cell growth. Topotecan is an FDA approved drug used to treat ovarian cancer that is still present after treatment with chemotherapy. It is also used to treat recurrent ovarian cancer (patients whose cancer returns after they have been cancer-free for a period of time). Before treatment starts, you will have a complete physical exam, routine blood tests (about 2-3 teaspoons), a chest x-ray, and a CT scan or MRI. Women who are able to have children must have a negative blood pregnancy test. There are 2 phases to this study. In the first phase, 3 different dose levels of topotecan are being studied. The dose of topotecan that you receive will depend on when you are enrolled. It will also depend on whether or not other participants had side effects from their treatment. Although the dose of topotecan will vary, the dose of gefitinib is the same for all participants. Up to 6 participants may be treated at each dose. The goal of this portion of the study is to find the highest safe dose of this drug combination. Up to 18 patients will be treated on this part of the study. Once the highest safe dose of topotecan has been found, the second phase of the study will begin. In this phase, all participants will receive the same dose of topotecan and gefitinib. Up to 40 patients will be enrolled in this part of the study (but 6 will be from the 1st portion of the study. Each treatment cycle is 28 days long. You will take one gefitinib tablet by mouth every day beginning on Day 1. In addition, you will be given topotecan through a catheter (tube) placed in a vein over 30 minutes on Days 1, 8, and 15. Blood tests to check your kidney, liver, and bone marrow function and a complete checkup (physical examination, including a pelvic and rectal exam) will be done before each course of therapy and a month after treatment ends. About 2-3 teaspoons of blood will be collected for routine blood tests each time blood is drawn during this study. Follow up CT scans or MRI scans will be done after every 2 to 3 cycles to evaluate your response to treatment. You will be taken off study if your disease gets worse or intolerable side effects occur. If you have a complete response to this therapy (no evidence of cancer) then treatment will continue for an additional 6 months and then stop. All treatment is given on an outpatient basis at UTMDACC. You will be monitored for at least 30 days after your last dose of therapy. If you have side effects related to this treatment combination, you will be monitored longer (until the side effects have gone away). This is an investigational study. Both gefitinib and topotecan are FDA approved and commercially available. However, their use together in this study is investigational. A total of up to 52 patients will take part in this study. All will be enrolled at UTMDACC.
Interventions
DRUGTopotecan
Phase I Starting Dose: 2 mg/m\^2 by vein Weekly Over 30 Minutes on Days 1, 8, and 15. Phase II: MTD dose from Phase I by vein weekly on Days 1, 8, and 15.
DRUGGefitinib
Phase I: 250 mg by mouth daily for 28 Days. Phase II: 250 mg by mouth daily for 28 Days.
Sponsors
AstraZeneca
GlaxoSmithKline
M.D. Anderson Cancer Center
Study design
Allocation
NA
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Healthy volunteers
No
Inclusion criteria
* Women with platinum-resistant, histologically confirmed epithelial ovarian, fallopian tube or peritoneal cancer. Resistance is defined as: Progression of disease during platinum chemotherapy, or progression of disease within 6 months of completing platinum chemotherapy, or failure to achieve a complete response, with persistent macroscopic disease, after an adequate trial of primary therapy. * EGF-R expression must be positive (e.g., 1+ or greater) See appendix G. * Patients with a known hypersensitivity to platinum compounds, who have failed a desensitization regimen, or in the opinion of the investigator, are not good candidates for desensitization, are eligible. * Patients must have measurable disease. * Unlimited number of prior chemotherapy regimens are allowed. * Zubrod performance status \</= 2. * Patients must have adequate hepatic, renal, and bone marrow function, defined as serum creatinine \</= 2 mg/dl (estimated creatinine clearance 50 ml/min); total bilirubin \< /=2.0 X the upper limit of normal (ULN); alanine aminotransferase (ALT) \</= 2X ULN; white blood count (WBC) \>/= 3,000/mm3; absolute neutrophil count (ANC) \>/= 1,500/mm3; platelets \>/= 100,000/mm3. * At least three weeks must have elapsed from completion of chemotherapy or radiation therapy. * At least 30 days must have elapsed from completion of treatment with a non-approved or investigational drug. * Patients must sign an informed consent indicating that they are aware of the investigational nature of the study, in keeping with the policies of the hospital. The only approved consent is appended to this protocol. * Women of childbearing potential must be willing to practice acceptable methods of birth control to prevent pregnancy.
Exclusion criteria
* Patients with borderline or low malignant potential tumors are not eligible. * Patients who have had prior therapy with topoisomerase I inhibitors. * Patients who are pregnant or lactating. * Concurrent chemotherapy, radiation therapy, or surgery (excluding palliative radiation). * Concurrent, uncontrolled, medical or psychiatric disorders. * Patients with an active infection. * Patients with a known hypersensitivity to topotecan or iressa. * Patients with severe cardiovascular disease (i.e. arrhythmias requiring chronic treatment or congestive heart failure) (NYHA classification III or IV). * History of other malignancy (except nonmelanoma skin cancer or carcinoma in situ of the cervix), unless in complete remission and off all therapy for that disease for a minimum of 5 years. * Patients with overt psychosis or mental disability or otherwise incompetent to give informed consent. * Patients who have had prior anti-EGFR therapy (i.e. Tarceva, Cetuximab). * Evidence of any other significant clinical disorder or laboratory finding that makes it undesirable for the subject to participate in the trial. * Concomitant use of phenytoin, carbamazepine, rifampicin, barbiturates, or St. John's Wort. * Any evidence of clinically active interstitial lung disease (patient with chronic stable radiographic changes who are asymptomatic are eligible).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Dose Limiting Toxicity (DLT) | Continual reassessment method, prior to each 28 day cycle, an average of 60 days | Dose-limiting toxicity defined as any Grade 4 hematological toxicity and any \> Grade 3 non-hematologic toxicity. The DLT (dose-limiting toxicity) is defined as any Grade 4 hematological toxicity and any \> Grade 3 non-hematologic toxicity. |
| Maximum Tolerated Dose (MTD) of Topotecan | At end of first course, prior to each new course (28 day cycle). Continual reassessment method (CRM) during each course for toxicity, an average of 60 days | Maximum tolerated dose is highest dose level in which 6 patients treated with at most 1 experiencing DLT. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Response Rate | 61 weeks | Measurable disease defined as at least one lesion that can be accurately measured in at least one dimension. Complete Response (CR): disappearance of all target and non-target lesions and no evidence of new lesions. Partial Response (PR): At least 30% decrease in sum of longest dimensions (LD) of all target measurable lesions. Increasing Disease: At least a 20% increase in sum of LD of target lesions taking as reference smallest sum LD or appearance of new lesions within 8 weeks of study entry. Progression on existing non-target lesions, other than pleural effusions without cytological proof of neoplastic origin. Death due to disease without prior objective documentation of progression. Global deterioration in health status attributable to disease requiring a change in therapy without objective evidence of progression. |
Countries
United States
Participant flow
Recruitment details
The study was activated on 09/02/2004 and closed to new patient entry on 01/10/2007. All recruitments were done in a medical clinic setting.
Participants by arm
| Arm | Count |
|---|---|
| Phase 1 Dose Level 1 Topotecan 2 mg/m2 IV on Days 1, 8, and 15 plus daily Gefitinib 250 mg given PO | 3 |
| Phase 1 Dose Level 2 Topotecan 3 mg/m2 IV on Days 1, 8, and 15 plus daily Gefitinib 250 mg given PO | 3 |
| Phase 1 Dose Level 3 Topotecan 4 mg/m2 IV on Days 1, 8, and 15 plus daily Gefitinib 250 mg given PO | 3 |
| Expansion Phase Topotecan 4 mg/m2 IV on Days 1, 8, and 15 plus daily Gefitinib 250 mg given PO | 10 |
| Total | 19 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 |
|---|---|---|---|---|---|
| Overall Study | Adverse Event | 0 | 0 | 0 | 2 |
| Overall Study | Disease Progression | 2 | 2 | 1 | 7 |
Baseline characteristics
| Characteristic | Phase 1 Dose Level 1 | Phase 1 Dose Level 2 | Phase 1 Dose Level 3 | Expansion Phase | Total |
|---|---|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 0 Participants | 1 Participants | 2 Participants | 3 Participants | 6 Participants |
| Age, Categorical Between 18 and 65 years | 3 Participants | 2 Participants | 1 Participants | 7 Participants | 13 Participants |
| Age, Continuous | 55 years | 55 years | 68 years | 60 years | 60 years |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 1 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 3 Participants | 3 Participants | 3 Participants | 9 Participants | 18 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 1 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 1 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 1 Participants |
| Race (NIH/OMB) White | 3 Participants | 3 Participants | 3 Participants | 7 Participants | 16 Participants |
| Region of Enrollment United States | 3 participants | 3 participants | 3 participants | 10 participants | 19 participants |
| Sex: Female, Male Female | 3 Participants | 3 Participants | 3 Participants | 10 Participants | 19 Participants |
| Sex: Female, Male Male | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk |
|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 3 | 0 / 3 | 0 / 3 | 0 / 10 |
| other Total, other adverse events | 3 / 3 | 3 / 3 | 3 / 3 | 9 / 10 |
| serious Total, serious adverse events | 0 / 3 | 0 / 3 | 0 / 3 | 0 / 10 |
Outcome results
Primary
Dose Limiting Toxicity (DLT)
Dose-limiting toxicity defined as any Grade 4 hematological toxicity and any \> Grade 3 non-hematologic toxicity. The DLT (dose-limiting toxicity) is defined as any Grade 4 hematological toxicity and any \> Grade 3 non-hematologic toxicity.
Time frame: Continual reassessment method, prior to each 28 day cycle, an average of 60 days
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Phase 1 Dose Level 1 | Dose Limiting Toxicity (DLT) | 2 Dose Limiting Toxicities |
| Phase 1 Dose Level 2 | Dose Limiting Toxicity (DLT) | 3 Dose Limiting Toxicities |
| Phase 1 Dose Level 3 | Dose Limiting Toxicity (DLT) | 4 Dose Limiting Toxicities |
Primary
Maximum Tolerated Dose (MTD) of Topotecan
Maximum tolerated dose is highest dose level in which 6 patients treated with at most 1 experiencing DLT.
Time frame: At end of first course, prior to each new course (28 day cycle). Continual reassessment method (CRM) during each course for toxicity, an average of 60 days
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Phase 1 Dose Level 1 | Maximum Tolerated Dose (MTD) of Topotecan | 4 mg/m^2 |
Secondary
Response Rate
Measurable disease defined as at least one lesion that can be accurately measured in at least one dimension. Complete Response (CR): disappearance of all target and non-target lesions and no evidence of new lesions. Partial Response (PR): At least 30% decrease in sum of longest dimensions (LD) of all target measurable lesions. Increasing Disease: At least a 20% increase in sum of LD of target lesions taking as reference smallest sum LD or appearance of new lesions within 8 weeks of study entry. Progression on existing non-target lesions, other than pleural effusions without cytological proof of neoplastic origin. Death due to disease without prior objective documentation of progression. Global deterioration in health status attributable to disease requiring a change in therapy without objective evidence of progression.
Time frame: 61 weeks
Population: Two patients received only one cycle of treatment and therefore were not evaluable for response to therapy.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Phase 1 Dose Level 1 | Response Rate | Stable disease | 0 Participants |
| Phase 1 Dose Level 1 | Response Rate | Progressive disease | 2 Participants |
| Phase 1 Dose Level 1 | Response Rate | Complete response | 0 Participants |
| Phase 1 Dose Level 1 | Response Rate | Not evaluable | 0 Participants |
| Phase 1 Dose Level 1 | Response Rate | Partial response | 1 Participants |
| Phase 1 Dose Level 2 | Response Rate | Not evaluable | 0 Participants |
| Phase 1 Dose Level 2 | Response Rate | Progressive disease | 2 Participants |
| Phase 1 Dose Level 2 | Response Rate | Stable disease | 1 Participants |
| Phase 1 Dose Level 2 | Response Rate | Partial response | 0 Participants |
| Phase 1 Dose Level 2 | Response Rate | Complete response | 0 Participants |
| Phase 1 Dose Level 3 | Response Rate | Complete response | 0 Participants |
| Phase 1 Dose Level 3 | Response Rate | Partial response | 1 Participants |
| Phase 1 Dose Level 3 | Response Rate | Stable disease | 1 Participants |
| Phase 1 Dose Level 3 | Response Rate | Progressive disease | 1 Participants |
| Phase 1 Dose Level 3 | Response Rate | Not evaluable | 0 Participants |
| Expansion Phase | Response Rate | Progressive disease | 7 Participants |
| Expansion Phase | Response Rate | Complete response | 0 Participants |
| Expansion Phase | Response Rate | Partial response | 0 Participants |
| Expansion Phase | Response Rate | Stable disease | 1 Participants |
| Expansion Phase | Response Rate | Not evaluable | 2 Participants |